Previous 10 | Next 10 |
home / stock / trgnf / trgnf news
Strasbourg (France), January 22, 2024 - 08:00 am CET TRANSGENE (Paris: TNG) today announced its financial reporting dates for 2024. March 27, 2024: 2023 Fiscal Year Results May 14, 2024: First Quarter 2024 Financial Results May 15, 2024: Annual Shareholders' Meetin...
Transgene and NEC plan to start an extension of the randomized Phase I trial into a randomized Phase I/II study in 2024 to further demonstrate the potential of TG4050 as an adjuvant treatment of head and neck cancers Strasbourg, France & Tokyo, Japan, January 8, 2024, 5:45 ...
Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of Arnaud Dubarry as Chief Financial Officer (CFO), effective January 1, 2024. Arnaud D...
2023-11-08 09:59:18 ET More on Transgene S.A. Transgene SA (TRGNF) Q2 2023 Earnings Call Transcript Historical earnings data for Transgene S.A. Financial information for Transgene S.A. For further details see: Transgene reports Q3 results
Transgene continues to advance its innovative immunotherapy pipeline, with key clinical development catalysts expected in the next 12 months Financial visibility until the end of 2024 Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops v...
The Phase I Part B will evaluate the combination of BT-001 and pembrolizumab in solid tumors, including melanoma Regulatory News: Transgene (Euronext Paris: TNG) , a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent Internatio...
2023-09-20 15:08:03 ET Transgene SA (TRGNF) Q2 2023 Earnings Conference Call September 20, 2023 12:00 PM ET Company Participants Lucie Larguier - Head of Investor Relations Alessandro Riva - Chairman and Chief Executive Officer Jean-Philippe Del - Vice President ...
Promising data from ongoing clinical trials of neoantigen cancer vaccine TG4050 and HPV-positive cancer therapeutic vaccine TG4001 presented at key congresses in H1 2023 Immunogenicity clinical data from ongoing trials confirm mechanism of action of Transgene’s ther...
Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that it has received $15.3 million (€ 14.0 million) as a result of the full disposal of its minority stake in a Chinese...
New immunological data assessed by tetramer staining confirms the induction of T cell responses in treated patients All trial patients treated with TG4050 monotherapy continue to remain in remission to date Transgene and NEC are preparing a Phase II trial to further demonstrate the potent...
News, Short Squeeze, Breakout and More Instantly...
Transgene S.A. Company Name:
TRGNF Stock Symbol:
OTCMKTS Market:
Patient screening and enrollment initiated for the Phase II part of the international randomized Phase I/II trial with an overall sample size of approximately 80 patients. Last patient enrollment for Phase II part expected in Q4 2025. Strasbourg, France, June 3, 2024, 7:30 a....
TG4050: Exciting Phase I data presented at AACR 2024 demonstrating first signs of clinical benefit in adjuvant setting for head and neck cancer Phase II part of randomized trial to start in coming weeks New clinical data expected on TG4001, TG6050 and BT-001 in H2 2024 Financial vis...
Strasbourg, France, April 24, 2024, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene’s shar...